TABLE 2.
Selection of polymorphisms in new infections after therapy with AL, AQ/SP, or DP
| Gene | SNPc | Prevalence (%) in baseline samplesa | Selection (%) in new infections after prior therapy withb: |
Selection byd: |
||||
|---|---|---|---|---|---|---|---|---|
| AL (n = 48) | AQ-SP (n = 13) | DP (n = 9) | AL | AQ-SP | DP | |||
| pfcrt | K76T | 72.7 | 52.1 | 76.9 | 77.8 | WT (0.008) | No (0.99) | No (0.96) |
| pfmdr1 | N86Y | 36.0 | 18.7 | 61.5 | 33.3 | WT (0.025) | No (0.13) | No (0.84) |
| Y184F | 66.7 | 45.8 | 69.2 | 77.8 | WT (0.009) | No (0.91) | No (0.39) | |
| D1246Y | 9.3 | 6.2 | 7.7 | 0 | No (0.71) | No (0.76) | No (0.42) | |
| pfdhfr | S108N | 30.8 | 76.9 | M (0.005) | ||||
| N51I | 30.8 | 61.5 | M (0.05) | |||||
| C59R | 28.2 | 76.9 | M (0.002) | |||||
| pfdhps | A437G | 76.9 | 69.2 | No (0.41) | ||||
| K540E | 0 | 0 | No | |||||
a
n = 150 for pfcrt and pfmdr1; n = 39 for pfdhfr and pfdhps.
b
Proportions of infections classified as mixed or mutant at each allele are shown.
c
SNP, single-nucleotide polymorphism.
d
Values indicate whether statistically significant selection was toward the wild-type (WT) sequence or the mutant (M) sequence or whether there was no selection observed (No); for these assessments, P values are shown in parentheses.